Home › Companies › Agios Pharmaceuticals, Inc. › 2025-2026

Agios Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Agios Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-18 (Item 5.07 on EDGAR). Page generated 04 October 2026.

6Ballot items
253Asset managers
1,642Fund votes
2026-06-18Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Agios Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Agios Pharmaceuticals, Inc.

These tallies are Agios Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Agios Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-06-18
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Rahul Ballal, Ph.D.	40,145,081	--	--	5,943,999	2,554,446	Majority: yes
Elect Director: Brian Goff	45,757,238	--	--	331,843	2,554,446	Majority: yes
Elect Director: Cynthia Smith	31,496,376	--	--	14,592,704	2,554,446	Majority: yes
2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.	43,396,045	1,086,059	1,606,976	--	2,554,446	Passed
3. The Company's stockholders approved the 2023 Plan Amendment.	43,549,751	2,527,678	11,651	--	2,554,446	Passed
4. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.	48,511,213	116,938	15,376	--	0	Passed

Source: Agios Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-18 — read the filing on EDGAR.

How asset managers voted at the Agios Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 253 asset managers that disclosed a Agios Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To vote, on an advisory basis, to approve the compensation paid to our named executive officers.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 5 wordings of this item as funds reported it.

98% Passed · of votes cast

FOR 98%

FOR: 43,396,045AGAINST: 1,086,059

Agios Pharmaceuticals, Inc.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 43,396,045 for, 1,086,059 against — passed, per its Form 8-K filed 2026-06-18 (Item 5.07). Of all 59,471,609 outstanding shares: 73% for, 2% against (75% of the company cast a for/against vote).

The 253 asset managers below cast 97% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 93%

FOR: 92.8%AGAINST: 2.6%ABSTAIN: 3.2%SPLIT: 1.4%NOT VOTED: 0.0%

Largest asset managers voting on “To vote, on an advisory basis, to approve the compensation paid to our named executive officers.” at Agios Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	6,099,752	3	6	For
BlackRock	5,175,444	134	0	For
FARALLON CAPITAL MANAGEMENT, L.L.C.	4,562,559	0	0	For
State Street	3,327,099	1,936	0	For
Lynx1 Capital Management LP	2,959,109	0	0	For
Erste Asset Management GmbH	2,704,900	0	0	For
T. Rowe Price	2,466,095	0	0	For
Fidelity	1,613,748	0	0	For
BNP Paribas Asset Management Holding S.A.	0	0	1,575,776	Abstain
GEODE CAPITAL MANAGEMENT, LLC	1,472,415	0	0	For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	1,323,380	0	0	For
Frazier Life Sciences Management, L.P.	1,256,080	0	0	For
Delaware/Macquarie	1,158,514	0	0	For
GW&K Investment Management, LLC	323,073	0	0	Split
Charles Schwab	959,703	0	0	For
Rock Springs Capital Management LP	799,163	0	0	For
ARMISTICE CAPITAL, LLC	759,597	0	0	For
Nuveen	722,441	0	0	For
TIAA	707,224	0	0	For
DE Shaw	629,582	0	0	For
MPM BioImpact LLC	589,198	0	0	For
SCS Capital Management LLC	553,152	0	0	For
Dimensional	485,846	0	0	For
Northern Trust	463,629	0	0	For
Legal & General Investment Management Ltd	0	418,350	0	Against

Showing the 25 largest of 253 asset managers. See all 253 in the interactive database.

2. To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Brian Goff

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 45,757,238WITHHELD: 331,843

Agios Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Brian Goff”): 45,757,238 for, 331,843 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,471,609 outstanding shares: 77% for, 0.6% withheld (77% of the company cast a for/withheld vote).

The 68 asset managers below cast 100% of the shares they voted on this item FOR (20,483,954 for, 0 against).

FOR 99.9%

FOR: 20,483,954 (100.0%)ABSTAIN: 8,658 (0.0%)

Largest asset managers voting on “To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a thr” at Agios Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	5,612,263	1	For
BlackRock	2,942,277	0	For
Erste Asset Management GmbH	2,704,900	0	For
State Street	2,202,586	23	For
Fidelity	1,606,123	0	For
Delaware/Macquarie	1,158,514	0	For
T. Rowe Price	858,121	0	For
TIAA	707,224	0	For
Charles Schwab	479,723	0	For
Dimensional	353,624	0	For
AMG FUNDS	272,612	0	For
First Trust	150,541	0	For
Equitable	124,191	0	For
American Century	121,737	0	For
Invesco	111,394	0	For
QUANTITATIVE MASTER SERIES LLC	91,876	0	For
MERIDIAN FUND INC	86,352	0	For
JPMorgan	83,229	0	For
ProShares	55,683	0	For
ALPS ETF Trust	47,229	0	For
AIG/SunAmerica	45,441	0	For
Harbor ETF Trust	43,269	0	For
Lincoln Financial	40,487	0	For
Brighthouse	35,420	3,915	For
Northwestern Mutual	38,434	0	For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

3. To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Cynthia Smith

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

68% Majority: yes · of votes cast

FOR 68%WITHHELD 32%

FOR: 31,496,376WITHHELD: 14,592,704

Agios Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Cynthia Smith”): 31,496,376 for, 14,592,704 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,471,609 outstanding shares: 53.0% for, 25% withheld (77% of the company cast a for/withheld vote).

The 68 asset managers below cast 100% of the shares they voted on this item FOR (12,966,611 for, 0 against).

FOR 63%ABSTAIN 37%

FOR: 12,966,611 (63.3%)ABSTAIN: 7,526,002 (36.7%)

Largest asset managers voting on “To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a thr” at Agios Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	5,612,215	49	For
BlackRock	0	2,942,277	Abstain
Erste Asset Management GmbH	2,704,900	0	For
State Street	15,642	2,186,967	Abstain
Fidelity	1,575,310	30,813	For
Delaware/Macquarie	0	1,158,514	Abstain
T. Rowe Price	208,574	649,547	Abstain
TIAA	707,224	0	For
Charles Schwab	479,723	0	For
Dimensional	353,624	0	For
AMG FUNDS	272,612	0	For
First Trust	150,541	0	For
Equitable	3,491	120,700	Abstain
American Century	121,737	0	For
Invesco	111,394	0	For
QUANTITATIVE MASTER SERIES LLC	0	91,876	Abstain
MERIDIAN FUND INC	86,352	0	For
JPMorgan	0	83,229	Abstain
ProShares	55,683	0	For
ALPS ETF Trust	47,229	0	For
AIG/SunAmerica	45,441	0	For
Harbor ETF Trust	43,269	0	For
Lincoln Financial	1,787	38,700	Abstain
Brighthouse	19,125	20,210	Abstain
Northwestern Mutual	0	38,434	Abstain

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

4. To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Rahul Ballal, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 40,145,081WITHHELD: 5,943,999

Agios Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Rahul Ballal, Ph.D.”): 40,145,081 for, 5,943,999 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,471,609 outstanding shares: 68% for, 10% withheld (77% of the company cast a for/withheld vote).

The 68 asset managers below cast 100% of the shares they voted on this item FOR (17,489,946 for, 0 against).

FOR 85%ABSTAIN 15%

FOR: 17,489,946 (85.3%)ABSTAIN: 3,002,667 (14.7%)

Largest asset managers voting on “To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a thr” at Agios Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	5,612,245	19	For
BlackRock	2,942,277	0	For
Erste Asset Management GmbH	2,704,900	0	For
State Street	15,731	2,186,878	Abstain
Fidelity	1,606,123	0	For
Delaware/Macquarie	1,158,514	0	For
T. Rowe Price	208,574	649,547	Abstain
TIAA	707,224	0	For
Charles Schwab	479,723	0	For
Dimensional	353,624	0	For
AMG FUNDS	272,612	0	For
First Trust	150,541	0	For
Equitable	84,451	39,740	For
American Century	121,737	0	For
Invesco	111,394	0	For
QUANTITATIVE MASTER SERIES LLC	91,876	0	For
MERIDIAN FUND INC	86,352	0	For
JPMorgan	83,229	0	For
ProShares	55,683	0	For
ALPS ETF Trust	47,229	0	For
AIG/SunAmerica	45,441	0	For
Harbor ETF Trust	43,269	0	For
Lincoln Financial	1,787	38,700	Abstain
Brighthouse	35,420	3,915	For
Northwestern Mutual	0	38,434	Abstain

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

5. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATEDCompany result: Passed

Combines 3 wordings of this item as funds reported it.

99.7% Passed · of votes cast

FOR 99.7%

FOR: 48,511,213AGAINST: 116,938

Agios Pharmaceuticals, Inc.’s own tally for this item (“4. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”): 48,511,213 for, 116,938 against — passed, per its Form 8-K filed 2026-06-18 (Item 5.07). Of all 59,471,609 outstanding shares: 82% for, 0.2% against (82% of the company cast a for/against vote).

The 68 asset managers below cast 99.9% of the shares they voted on this item FOR (20,488,608 for, 89 against).

FOR 99.9%

FOR: 20,488,608 (100.0%)AGAINST: 89 (0.0%)ABSTAIN: 3,915 (0.0%)

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm f” at Agios Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,612,264	0	0	For
BlackRock	2,942,277	0	0	For
Erste Asset Management GmbH	2,704,900	0	0	For
State Street	2,202,520	89	0	For
Fidelity	1,606,123	0	0	For
Delaware/Macquarie	1,158,514	0	0	For
T. Rowe Price	858,121	0	0	For
TIAA	707,224	0	0	For
Charles Schwab	479,723	0	0	For
Dimensional	353,624	0	0	For
AMG FUNDS	272,612	0	0	For
First Trust	150,541	0	0	For
Equitable	124,191	0	0	For
American Century	121,737	0	0	For
Invesco	111,394	0	0	For
QUANTITATIVE MASTER SERIES LLC	91,876	0	0	For
MERIDIAN FUND INC	86,352	0	0	For
JPMorgan	83,229	0	0	For
ProShares	55,683	0	0	For
ALPS ETF Trust	47,229	0	0	For
AIG/SunAmerica	45,441	0	0	For
Harbor ETF Trust	43,269	0	0	For
Lincoln Financial	40,487	0	0	For
Brighthouse	35,420	0	3,915	For
Northwestern Mutual	38,434	0	0	For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

6. TO APPROVE AN AMENDMENT TO THE AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE THEREUNDER BY 2,000,000 SHARES.

COMPENSATIONCompany result: Passed

95% Passed · of votes cast

FOR 95%

FOR: 43,549,751AGAINST: 2,527,678

Agios Pharmaceuticals, Inc.’s own tally for this item (“3. The Company's stockholders approved the 2023 Plan Amendment.”): 43,549,751 for, 2,527,678 against — passed, per its Form 8-K filed 2026-06-18 (Item 5.07). Of all 59,471,609 outstanding shares: 73% for, 4% against (77% of the company cast a for/against vote).

The 68 asset managers below cast 96% of the shares they voted on this item FOR (17,028,290 for, 757,478 against).

FOR 96%

FOR: 17,028,290 (95.7%)AGAINST: 757,478 (4.3%)ABSTAIN: 3,915 (0.0%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE ” at Agios Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,606,787	5,476	0	For
BlackRock	2,942,277	0	0	For
State Street	2,199,683	2,926	0	For
Fidelity	1,301,585	304,538	0	For
Delaware/Macquarie	1,158,514	0	0	For
T. Rowe Price	858,121	0	0	For
TIAA	707,224	0	0	For
Charles Schwab	479,723	0	0	For
Dimensional	353,624	0	0	For
AMG FUNDS	0	272,612	0	Against
First Trust	150,541	0	0	For
Equitable	124,191	0	0	For
American Century	0	121,737	0	Against
Invesco	111,394	0	0	For
QUANTITATIVE MASTER SERIES LLC	91,876	0	0	For
MERIDIAN FUND INC	86,352	0	0	For
JPMorgan	83,229	0	0	For
ProShares	55,683	0	0	For
ALPS ETF Trust	47,229	0	0	For
AIG/SunAmerica	45,441	0	0	For
Harbor ETF Trust	43,269	0	0	For
Lincoln Financial	40,487	0	0	For
Brighthouse	35,420	0	3,915	For
Northwestern Mutual	38,434	0	0	For
ETFis Series Trust I	33,353	0	0	For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

Largest Agios Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Agios Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 59,471,609 shares outstanding at the time of that meeting.

Top Agios Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	10.26%
2	BlackRock	8.70%
3	FARALLON CAPITAL MANAGEMENT, L.L.C.	7.67%
4	State Street	5.60%
5	Lynx1 Capital Management LP	4.98%
6	Erste Asset Management GmbH	4.55%
7	T. Rowe Price	4.15%
8	Fidelity	2.71%
9	BNP Paribas Asset Management Holding S.A.	2.65%
10	GEODE CAPITAL MANAGEMENT, LLC	2.48%

Reported Agios Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Agios Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Farallon Capital Management, L.L.C.	9.95%	13G
BlackRock	9.68%	13F
Vanguard Group	9.41%	13F
State Street	5.66%	13F
D.E. Shaw	4.51%	13F
Geode Capital	2.47%	13F
Dimensional Fund Advisors	1.94%	13F
Morgan Stanley	1.50%	13F
Goldman Sachs	1.37%	13F
Citadel Advisors	1.29%	13F

Percentages above are of 59,471,609 shares outstanding, as reported by Agios Pharmaceuticals, Inc. on its Form 10-Q dated 2026-04-24 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Agios Pharmaceuticals, Inc.’s 10-Q dated 2026-04-24. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Agios Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-18, in the 2025-2026 proxy season, 253 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,642 separate fund positions. On the most widely held item on that ballot — To vote, on an advisory basis, to approve the compensation paid to our named executive officers. — the proposal passed with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Agios Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-18.

Agios Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).